semaglutide aging A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% Study: Popular GLP-1 Drug May

The parent compound, which is nontoxic, is extensively metabolized in the liver to form principally the sulfate and glucuronide conjugates which are also nontoxic and are rapidly excreted in the urine

Evidence suggests that breathwork improves heart rate variability and promotes resilience to stress

When insulin signaling via PI3K-PDPK1-AKT/PKB is impaired, as described above for the insulin resistant (IR) state, the MAPK signaling pathway in endothelial cells is enhanced

These effects are influenced by factors such as dosage and background medications

doi:10.26444/aaem/119994 Yu S, Yue S, Liu Z, Zhang T, Xiang N, Fu H